Active Ingredient History
Abexinostat is an experimental drug candidate for cancer treatment. It was developed by Pharmacyclics and licensed to Xynomic. and is in Phase II clinical trials for B-cell lymphoma. Pre-clinical study suggests the potential for treatment of different types of cancer as well. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Transitional Cell (Phase 1)
Endometrial Neoplasms (Phase 1)
Fallopian Tube Neoplasms (Phase 1)
Hamartoma (Phase 1)
Hematologic Neoplasms (Phase 1)
Hodgkin Disease (Phase 1/Phase 2)
Leukemia (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Lung Neoplasms (Phase 1)
Lymphoma (Phase 1/Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Mantle-Cell (Phase 1/Phase 2)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Melanoma (Phase 1)
Multiple Myeloma (Phase 1)
Neoplasms (Phase 1)
Neoplasms by Site (Phase 1)
Ovarian Neoplasms (Phase 1)
Sarcoma (Phase 1/Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Ureteral Neoplasms (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue